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Critical issues in pediatric lung transplantation 
Forty children (aged 1 to 18 years, 27 female and 13 male) have undergone heart-lung (21), double 
lung (17), and single lung (2) transplant procedures at our center from 1985 through April 1994. The 
indications for transplantation have been diverse, primary pulmonary hypertension (10), cystic 
fibrosis (11), congenital heart disease (10), arteriovenous malformation (3), emphysema (1), 
graft-versus-host disease (1), rheumatoid lung (1), cardiomyopathy (1), desquamative interstitial 
pneumonitis (1), and Proteus yndrome (1). The actuarial 1-year survival was 73% (mean follow-up 
2 years). One-year actuarial survival for disease groups ranged from 60% for cystic fibrosis to 90% 
for congenital heart disease. We have identified six issues critical to the patient and programatic 
survival of pediatric lung transplantation. Our experience and management strategies in these areas 
are reviewed. Cytomegalovirus: Cytomegalovirus disease developed in six of eight patients with 
cytomegalovirus mismatching (donor +/recipient - )  and in seven of 32 patients who survived more 
than 30 days (23%). All but cytomegalovirus donor -/recipient- patients were treated with 
ganciclovir for 4 weeks after transplantation. Obliterative bronchiolitis: Obliterative bronchiolitis 
developed in seven of 32 (25%) patients who survived more than 30 days. Obliterative bronchiolitis 
was manifest within the first posttransplantation year as a rapid decline in small airway function. 
Aggressive augmentation f immunosuppression has been used with little success. Posttransplanta- 
tion lymphoproliferative disease: Posttransplantation lymphoproliferative disease developed in five of 
32 (15%) patients who survived more than 30 days developed. One patient died (17% mortality) 
despite retransplantation. In four patients the disease resolved with reduction in immunosuppres. 
sion alone, and one required the addition of interferon alfa. Cystic fibrosis: We have changed our 
management strategies to avoid triple drug immunosuppression, perioperative blood and bronchial 
cultures, aggressive antimicrobial therapy, and exclusion of patients with panresistant organisms; 
this has resulted in elimination of infectious mortalities thus far in the pediatric ystic fibrosis 
group. Airways: In 21 heart-lung recipients with tracheal anastomoses we have had no airway 
complications. The double and single lung transplant recipients accounted for 34 bronchial and one 
tracheal anastomoses. Three (9%) bronchial stenoses developed. Two were treated with silicone 
stents and one with balloon dilation. Finances: The average charge for lung transplant evaluation was 
$18,000 and for transplantation, $175,000. (J THORAC CARDIOVASC SURG 1995;109:60-5) 
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Lung Transplant Registry, x which has recorded 
nearly 2000 lung transplants performed worldwide 
through 1992, only 96 (5%) of which were for 
patients between birth and 16 years of age. The 
International Society of Heart and Lung Transplan- 
tation's (ISHLT) 1993 Registry reported 1349 heart- 
lung transplant procedures, only 20% of which were 
for patients under the age of 18 years. 2Despite the 
late advent of lung transplantation technology into 
pediatric medicine, survival rates and quality of life 
in these children have been gratifying. The children 
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Fig. 1. Percent survival after transplantation, with the patients tratified according to their indication for 
transplantation. CHD, Congenital heart disease; CF, cystic fibrosis; PPH, primary pulmonary hypertension. 
are clearly beneficiaries of some very difficult lessons 
learned in the adult arena. However, as always, the 
children have much to teach us. We report here our 
experience in pediatric lung transplantation with 
emphasis on issues critical to the management and 
long-term well-being of these special patients. 
Patient group 
Forty children, aged 1 to 18 years, have undergone 
heart-lung (n = 21), double lung (n = 17), and single lung 
(n = 2) transplantation from 1985 through April 1994. 
Twenty-eight (70%) of these children were female and 12 
were male. The indications for transplantation have been 
primary pulmonary hypertension (n = 10), cystic fibrosis 
(CF) (n = 11), congenital heart disease (n = 10), arterio- 
venous malformation (n = 3), emphysema (n = 1), 
graft-versus-host disease (n = 1), rheumatoid lung (n = 
1), cardiomyopathy (n = 1), desquamative interstitial 
pneumonitis (n = 1), and Proteus yndrome (n = 1). The 
congenital heart anomalies in our 10 patients were trans- 
position of the great arteries (n = 5), ventricular septal 
defect (n = 2), truncus arteriosus (n = 1), hypoplastic left 
heart syndrome (n = 1), and double-outlet right ventricle 
(n = 1). Nine (22%) of the 40 recipients had at least one 
major thoracic operation before transplantation. Two of the 
nine patients had two sternotomies, one had two thoracoto- 
mies, and one had two sternotomies and two thoracotomies. 
One patient underwent retransplantafion forposttransplan- 
tation lymphoproliferafive disease (PTLD). 
A review of our center's recipient selection, implanta- 
tion techniques, donor evaluation, and lung preservation, 
immunosuppression, monitoring and treatment of infec- 
tion and rejection has been previously reported)' 4 
Survival. Actuarial survival at 1 year for the group as a 
whole was 73% at a mean follow-up of 2 years (range 0.5 
to 8 years). One-year actuarial survival for individual 
disease groups is depicted in Fig. 1 and ranged from a low 
of 60% for patients with CF to 90% for patients with 
congenital heart disease (CHD). 
Critical issues. We have chosen six issues critical to 
survival in pediatric lung transplantation, both to the 
individual patients and to the programs themselves. Our 
experience and management s rategies in these areas re 
reviewed herein. 
Cytomegalovirus (CMV). Thirty-two patients survived 
more than 30 days after transplantation. CMV disease, 
defined as the presence of CMV syndrome, pneumonitis, 
hepatitis, or enteritis, developed in seven patients (23%). 
Donor (D) and recipient (R) CMV serology was available 
on 30 of these 32 patients. Nineteen patients were D- /  
R - ,  and CMV disease developed in only one of these 
patients. This occurred in 1985, before the advent of 
ganciclovir, routine donor/recipient CMV screening, and 
the exclusive use of CMV negative blood products for 
transplant recipients. CMV pneumonitis developed after 
discharge on posttransplantation day 20, and the patient 
subsequently died of disseminated CMV. This has been 
our only CMV mortality, undoubtedly the result of blood 
product ransmission. 
Eight patients were CMV mismatched, D+/R- ,  and 
CMV disease developed in six (75%) of them. CMV 
pneumonitis developed in four patients and CMV syn- 
drome developed in two. One patient was D- /R+ and 
two patients were D +/R+; no CMV disease developed in 
these patients; however, CMV shedding was detected in 
their bronchial avage samples. 
Our present approach to the issue of CMV in pediatric 
lung transplant recipients includes the following: 
1. Donor and recipient serologies are always obtained 
and do not affect donor or recipient selection. CMV 
serology is part of the routine screening of all lung 
recipients at their semiannual follow-up visits. In addition, 
bronchoalveolar lavage fluid and lung biopsy samples are 
routinely screened for CMV. 
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2. All lung transplant recipients who require transfu- 
sions receive CMV negative blood and blood products. 
3. All CMV positive recipients or mismatched recipi- 
ents (D+/R- )  receive intravenous ganciclovir for a min- 
imum of 4 weeks (10 mg per kg per day in two divided 
doses for 2 weeks and 5 mg/kg per day once a day for 2 
weeks). In the past, we have recommended 3 months of 
high-dose (650 mg/m z per day) oral acyclovir to these 
patients; however, a randomized prospective study in 
pediatric liver recipients has shown this to be of no added 
benefit in preventing CMV disease. In addition, pharma- 
cokinetic studies have revealed both very poor absorption 
of acyclovir in children and correspondingly low serum 
levels. 5 We have, therefore, discontinued this practice. 
4. The recent availability of CMV-specific immunoglob- 
ulin carries with its hope of passive CMV immunity avery 
high price tag. We intend to examine its efficacy as an 
adjuvant to ganciclovir in our high-risk population in our 
next five patients. We have not previously used polyclonal 
immunoglobulin preparations. 
Obliterative bronchiolitis (OB). In our 32 patients who 
survived more than 30 days, an average of two episodes of 
acute cellular rejection (A2A or greater) occurred per 
patient within 90 days, irrespective of the primary immu- 
nosuppressant, cyclosporine or FK 506. However, from 90 
days to 2 years, the FK 506 group had significantly less 
acute cellular rejection (2.2 versus 0.4 rejection episodes 
per patient) than the cyclosporine group (p < 0.001, 
Fisher). OB developed in five patients (30%) in the 
cyclosporine group and two (12%) in the FK 506 group. 
The incidence of OB in the pediatric lung transplant 
group as a whole was 25%. Three (40%) of the seven 
children with OB had CMV disease and all were CMV 
negative recipients. All seven children with OB demon- 
strated a dramatic and often sudden drop in small airway 
function as measured by forced expiratory volume in 1 
second and maximum idexpiratory flow rate within the 
first posttransplantation year. Only one patient has shown 
significant improvement in airway function with aggressive 
augmentation f immunosuppression. Our treatment pro- 
tocol for OB is two courses of intravenous steroids and at 
least one course of antilympholytic therapy. 
This aggressive approach has yielded little success. 
Inhaled cyclosporine, total lymphoid irradiation, and pho- 
tophoresis are all potential treatment options focused on 
further augmentation f immunosuppression. All of these 
therapies would have to be considered xperimental t 
this time, and although we have limited experience with 
inhaled cyclosporine i  adults (10 patients) and in chil- 
dren (one patient), one child with OB recently underwent 
successful retransplantation. 
PTLD. In a 10-year etrospective analysis of heart and 
lung transplantation with cyclosporine-based immunosup- 
pression, we found that PTLD was significantly more 
likely to develop within the first posttransplantation year 
in the lung transplant recipient han in the heart recipient 
(7.9% versus 1.8%, p = 0.02). In the same study it was 
apparent that the child was at much greater isk than the 
adult for the development of PTLD (9.7% versus 3.5%, 
p = 0.08). 6 Thus it has not surprised us that PTLD 
developed in 15% of our pediatric lung transplant recip- 
ient group who survived more than 30 days. Five children 
have had PTLD; in all the disease became manifest in the 
lung within the first year after transplantation, and all 
were Epstein-Barr virus (EBV) negative recipients. One 
patient (17%) died despite retransplantation. Three pa- 
tients were rendered isease free with reduction in immu- 
notherapy alone, and the fourth required the addition of 
interferon alfa for remission. Ten other children were 
EBV negative recipients, two had EBV syndrome, and 
one had EBV hepatitis without PTLD. 
In addition to maintaining a high index of suspicion for 
this disease, we now also obtain donor and recipient EBV 
serology. In the event of an EBV mismatch, D+/R- ,  we 
reduce immunosuppression to single-agent therapy (FK 
506 or cyclosporine) and aggressively monitor EBV serol- 
ogy in the recipient's serum, as well as special EBV stains 
and probes of lung biopsy specimens. We have reserved 
the use of interferon alfa for patients in whom computed 
tomographic scanning of the chest fails to demonstrate 
significant resolution of PTLD lesions in the lung within 4 
to 8 weeks after their reduction in immunotherapy. We 
also use both ganciclovir ntravenously and acyclovir orally 
during the early course of PTLD. However, data to 
suggest hat this is truly beneficial are scant. One of our 
four children who obtained remission from PTLD had 
recurrence 5 years later with cervical adenopathy and 
EBV syndrome. She has continued to do well receiving 
reduced immunosuppression. 
CF. The 1993 ISHLT Registry reported that CF was 
the indication for double lung transplantation i more 
than 60% of children undergoing the procedure. Another 
18% of children who underwent heart-lung transplanta- 
tion also had CF. Thus not only has CF become the 
leading indication for lung transplantation i  children, it 
carries the highest risk. One-year survival after double- 
lung transplantation for CF is approximately 60%. Along 
with the problems associated with all other patients with 
end-stage lung disease, patients with CF have tracheal 
colonization with organisms that are difficult to treat with 
antibiotics. Patients with CF also commonly are malnour- 
ished and have chronic sinusitis and osteoporosis. Indwell- 
ing intravenous or enteral catheters are frequently in 
place at the time of transplantation. 
In our entire patient group, we had 31 major infections: 
Ten were bacterial, and 80% occurred in patients with CF; 
eight were viral, and 50% occurred in patients with 
CF; two were yeast, and 100% occurred in patients 
with CF. Seven patients died of infection (11), four (60%) 
of whom had CF. We have learned from our patients with 
CF that infection poses their greatest risk, and we have 
thus altered our approach to them, such that our last four 
patients with CF have all been discharged without a major 
infection after double lung transplantation. 
1. The presence of Pseudomonas cepacia in the airway 
or sinuses of a patient with CF is a contraindication to
lung transplantation. 
2. Blood cultures are obtained during the transplant 
procedure and in the immediate postoperative period. 
These cultures are positive for Pseudomonas in about 50% 
of CF recipients. Early identification and sensitivity of 
blood-borne organisms i tremendously helpful in direct- 
ing specific and aggressive antibiotic therapy. Antibiotics 
include an aminoglycoside and at least one other agent 
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directed against he patient's organisms. Amphotericin is
used aggressively for any indication of yeast colonization. 
This antibiotic regimen is continued initially for a mini- 
mum of 2 weeks. Bronchoscopy and bronchoalveolar 
lavage are done routinely within 24 to 48 hours after 
transplantation to further identify organisms that may 
have colonized the transplanted airway in the early post- 
operative period. 
3. Triple-drug immunosuppression is avoided now in all 
recipients with CF. They receive steroids only during the 
operation and on postoperative day 1. Thereafter, FK 506 
(or cyclosporine) and azathioprine are the only immuno- 
suppressive agents. 
4. We do not recommend sinus ablation before or after 
transplantation. This has not been of specific benefit and 
is attended with recolonization within 6 months. Further- 
more, we have not documented that sinusitis per se has 
been a significant contributing factor to posttransplanta- 
tion infections in our patients with CF. 
Airways. We use polypropylene sutures for all airway 
anastomoses. We no longer use omental or vascularized 
pedicl e wraps for any airway anastomosis. In heart-lung 
recipients, we do interpose a strip of pericardium between 
the trachea nd aorta to provide some barrier to infectious 
organisms that might lead to an aortic mycotic aneurysm. 
We have not as yet pursued techniques designed specifi- 
cally to revascularize the airway. All our heart-lung trans- 
plants in children are performed with end-to-end tracheal 
anastomoses just above the carina. This is done with a 
running 3-0 polypropylene suture on the membranous 
portion and a separate running suture on the cartilaginous 
portion. In 20 heart-lung recipients, we have had no 
airway complications and no aortic mycotic aneurysms. 
Only one double lung recipient had a tracheal anastomo- 
sis; all other double lung recipients and both single lung 
recipients had bronchial anastomoses. We perform our 
bronchial anastomoses with a running polypropylene su- 
ture on the membranous portion and interrupted figure- 
of-eight elescoping sutures on the cartilaginous portion. 
We have encountered one airway anomaly, a tracheal 
origin of the right upper lobe bronchus] The double and 
single lung recipients accounted for 34 bronchial and one 
tracheal anastomoses. There were three (9%) airway 
stenoses in the 34 bronchial anastomoses. Two were 
treated with a bronchial stent and one with balloon 
dilation. 
Finances. The average charge for a lung transplant 
evaluation at Children's Hospital of Pittsburgh, which 
usually involves a 72-hour admission, is $18,000 (range 
$12,000 to $28,000). The average charge for a lung 
transplant procedure and 3 weeks' hospitalization is
$175,000 (range $150,000 to $325,000). 
Discussion 
Despite the fact that CF, congenital heart disease, 
and primary pulmonary hypertension constitute the 
main indications for lung transplantation i chil- 
dren, a wide variety of end-stage lung diseases in 
children can be successfully treated by transplanta- 
tion. The survival statistics from our own and many 
other centers have been extremely gratifying. How- 
ever, those of us involved in this challenging en- 
deavor remain far from the summit of success. The 
exhilaration, for both physician and child alike of 
the restoration toward normality of heart and lung 
function after transplantation defies description. 
Having once experienced this thrill, nothing is more 
agonizing than to watch the breathlessness of OB 
ensue. It is incumbent on all of us involved in this 
field to pursue without respite a better understand- 
ing of the immunologic factors that lead to this 
devastating manifestation of chronic lung rejection. 
It seems, with the rapid Onset of OB, that additive 
and more potent immunosuppression as a means of 
treatment is too little too late. We must be able to 
better understand the disease, predict hose at risk, 
and devise a strategy of prevention. The clues to the 
puzzle of OB lie in the determination of why the 
bronchial epithelium is the antigenic target and 
what cytokines up-regulate ither humoral or cellu- 
lar components to such a destructive nd. Indeed, 
although CMV deserves further study and under- 
standing to prevent its disease, there is much evi- 
dence to suggest that it plays a role in immune 
up-regulation and therefore may be a significant 
factor in the development of OB. 8 
PTLD also remains a major concern to the pedi- 
atric organ recipient, particularly if the transplanted 
organ contains ignificant amounts of donor-derived 
lymphatic tissue, as in lung and small bowel. We are 
convinced that, at least for those patients in whom 
PTLD develops early after transplantation, PTLD is 
a donor-transmitted disease. EBV serology of donor 
and recipient is as important as is that of CMV, 
particularly in the child. Early detection and aggres- 
sive reduction in immunotherapy are keys to the 
successful treatment and management of PTLD. 
This disease underscores the critical importance of 
using and administering immunosuppressive agents, 
not in a "cook book" fashion, but individualized to 
each patient. 
Another significant challenge in pediatric lung 
transplantation is to improve the results in our 
largest patient population, that of CF. Ideally, in the 
near future genetic engineers will obviate the need 
for lung replacement therapy in these children. 
However, until such time, we must recognize that 
infection poses the greatest risk to lung recipients 
with CF and that lower immunosuppression a d 
aggressive antimicrobial diagnosis and therapy will 
improve the outcome. 
Finally, we the transplant physicians must address 
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the issue of cost. This is a painful and arduous task. 
Innovative and fiscally sound decisions must be 
made in a multiinstitutional and cooperative ffort 
to hold down and limit the costs involved in this 
astronomically expensive procedure. 
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Discussion 
Dr. J. Kent Trinkle (San Antonio, Tex.). Are you 
accepting mismatches--CMV positive donor organs into 
CMV negative patients? 
Dr. Armitage. Correct. We do not direct organs to 
CMV status and we will accept a mismatch. 
Dr. Trinlde. Am I correct hat you use only ganciclovir 
for prophylaxis? 
Dr. Armitage. That's correct. In the past we have used 
intravenous ganciclovir for 4 weeks. 
Dr. Trinlde. In the past we have had terrible problems 
with CMV, particularly with cytolytic therapy and specif- 
ically with OKT3. We then started using both prophylactic 
ganciclovir and immune globulin. The lung transplant 
literature contained nothing in this regard, but a fair 
amount of data from other transplant systems and bone 
marrow transplants indicated that the combination of the 
two is better than just one. 
Dr. Armitage. We have avoided, except early on, the use 
of cytolytic therapy in children specifically because of the 
increased risk of CMV and also EBV. 
Dr. Thomas M. Egan (Chapel Hill, N.C.). If you are 
going to bring up the issue of cost of transplantation, I 
think it is only fair to bring up the issue of cost of care of 
chronically ill children. Do you have any idea what the 
cost of care would have been until these children died 
without transplantation, because that is the other side of 
the equation? 
Dr. Armitage. The cost/benefit ratio is certainly an 
excellent point. Most of the children that we deal with 
have a fairly short life expectancy. However, the patient 
with CF can live for many years, and the cost is tremen- 
dous. 
Dr. Axel Haverich (Kiel, Germany). Something worri- 
some is the very high rate of OB in the pediatric age 
group. Were you able to identify special risk factors, or 
could you identify certain immunosuppressive regimens, 
such as FK 506, to have a beneficial effect on this 
complication? 
Dr. Armitage. The recognition and prevention of OB is 
probably the crux of the matter. In the larger population 
of adults, two major risk factors have been identified by 
multivariate analysis. The first is the frequency of acute 
cellular ejection as a major risk factor--more than two or 
three episodes in the first 3 months is a risk factor for the 
development of OB. The other factor is the development 
of CMV viral infection. Of 10 adult recipients who 
eventually had OB, nine had prior CMV infections. OB is 
much less prevalent in those who do not have CMV 
infections. Thus CMV and acute cellular rejection are the 
main issues. 
Dr. Haverieh. If you evaluate your adult population, 
does FK 506 make any difference? 
Dr. Armitage. Episodes of acute cellular rejection are 
less frequent in adults, and that may affect OB, but we 
have certainly not seen an effect in the pediatric group. 
Dr. Vaughn A. Starnes (Los Angeles, Calif.). What are 
you doing now with Eisenmenger's syndrome in your 
pediatric age group? 
Dr. Armitage. All 10 of these children underwent 
heart-lung transplantation, and even in retrospect, none 
of them probably would have been good candidates for 
single or double lung transplantation. They are a very 
special group, as you know. Many of them have had three 
or four prior procedures, and most of the cardiac defects 
in these younger children have been irreparable. We have 
had repairs of atrial septal defects, ventricular septal 
defects, and atrioventricular septal defects when the left- 
sided atrioventricular valve was reparable. Patent ductus 
arteriosus and transposition of the great arteries have 
been repaired concomitantly with double lung transplan- 
tation. A small number of children with atrial septal 
defects have undergone single lung transplantation. We 
do have one child with a ventricular septal defect who I 
think is a candidate for double lung transplantation rather 
than heart-lung transplantation. 
Dr. Trinlde. What do you use for bronchial stenoses? 
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We use the Palmaz stent, which was developed by Dr. 
Julio Palmaz, a vascular adiologist at our institution, and 
is made by Johnson & Johnson (King of Prussia, Pa.). It is 
a wire mesh vascular stent, such as you use in coronary or 
femoral arteries. It is available in various lengths and sizes 
and is very easy to put in. I highly recommend it. 
Dr. Armitage. We have used silicone rubber stents. I
know that Chip Bolman at the University of Minnesota 
has used chicken wire stents, and I think they have a lot of 
appeal. If the right upper lobe bronchus is very near, you 
can continue to ventilate and stent it. We used balloon 
dilation in one patient in whom the right upper lobe 
bronchus was right there, but I think that the mesh stent 
certainly has a role. 
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